GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Guardant Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$157.88−0.72 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $20.98B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$92.42 (+141.2%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Guardant Health, Inc. grew revenue 42.7% to $1.18B over the twelve months to Jun 30, 2026. Free cash flow was -$240.72M.
Revenue
$1.18B
+42.7% vs. a year earlier
Operating income
-$470.26M
TTM Q2 2026
Free cash flow
-$240.72M
TTM Q2 2026
EPS, diluted
-$3.49
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $20.98B
- P/E ratio
- –
- Price to sales
- 17.73
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1.15%
Fundamentals
- Revenue
- $1.18B
- Net income
- -$453.44M
- EPS, diluted
- -$3.49
- Free cash flow
- -$240.72M
- Book value per share
- -$1.68
- Diluted shares
- 133M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$1.18B+42.7% YoY
Gross profit
$769.16M+47.7% YoY
Operating income
-$470.26M
Net income
-$453.44M
EPS, diluted
-$3.49
Free cash flow
-$240.72M
Reported periodTrailing twelve months